Baillie Gifford & Co. cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,777,634 shares of the medical device company’s stock after selling 316,837 shares during the quarter. Baillie Gifford & Co. owned approximately 6.67% of DexCom worth $282,671,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Advisor Group Inc. raised its holdings in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 837 shares during the period. IFP Advisors Inc raised its holdings in DexCom by 30.5% during the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after acquiring an additional 568 shares during the period. Independent Portfolio Consultants Inc. raised its holdings in DexCom by 0.4% during the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after acquiring an additional 9 shares during the period. Janney Montgomery Scott LLC raised its holdings in DexCom by 9.2% during the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after acquiring an additional 250 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in DexCom by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after acquiring an additional 354 shares during the period.

TRADEMARK VIOLATION WARNING: This news story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://theolympiareport.com/2017/11/02/dexcom-inc-dxcm-holdings-reduced-by-baillie-gifford-co.html.

In related news, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total value of $123,050.10. Following the transaction, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at approximately $5,448,447.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew K. Balo sold 3,244 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $71.18, for a total transaction of $230,907.92. The disclosure for this sale can be found here. Insiders sold a total of 23,208 shares of company stock worth $1,597,567 over the last ninety days. 1.70% of the stock is currently owned by corporate insiders.

DXCM has been the topic of a number of recent analyst reports. BidaskClub cut DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Piper Jaffray Companies reissued a “buy” rating and set a $78.00 price target on shares of DexCom in a report on Wednesday, July 12th. BMO Capital Markets reissued a “buy” rating and set a $105.00 price target on shares of DexCom in a report on Thursday, July 13th. Cowen and Company reissued a “buy” rating and set a $90.00 price target on shares of DexCom in a report on Friday, July 14th. Finally, Zacks Investment Research raised DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company. DexCom presently has a consensus rating of “Buy” and a consensus target price of $72.19.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. DexCom’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period last year, the company posted ($0.24) EPS.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.